CA2813101C - Eph receptor expression in tumor stem cells - Google Patents

Eph receptor expression in tumor stem cells Download PDF

Info

Publication number
CA2813101C
CA2813101C CA2813101A CA2813101A CA2813101C CA 2813101 C CA2813101 C CA 2813101C CA 2813101 A CA2813101 A CA 2813101A CA 2813101 A CA2813101 A CA 2813101A CA 2813101 C CA2813101 C CA 2813101C
Authority
CA
Canada
Prior art keywords
cells
epha2
gbm
use according
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2813101A
Other languages
English (en)
French (fr)
Other versions
CA2813101A1 (en
Inventor
Angelo Luigi Vescovi
Elena Binda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
STEMGEN SpA
Original Assignee
STEMGEN SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by STEMGEN SpA filed Critical STEMGEN SpA
Publication of CA2813101A1 publication Critical patent/CA2813101A1/en
Application granted granted Critical
Publication of CA2813101C publication Critical patent/CA2813101C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2813101A 2010-10-01 2011-09-30 Eph receptor expression in tumor stem cells Active CA2813101C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10185930A EP2446895A1 (en) 2010-10-01 2010-10-01 EPH receptor expression in tumor stem cells
EP10185930.4 2010-10-01
PCT/EP2011/067114 WO2012042021A1 (en) 2010-10-01 2011-09-30 Eph receptor expression in tumor stem cells

Publications (2)

Publication Number Publication Date
CA2813101A1 CA2813101A1 (en) 2012-04-05
CA2813101C true CA2813101C (en) 2018-10-30

Family

ID=43856109

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2813101A Active CA2813101C (en) 2010-10-01 2011-09-30 Eph receptor expression in tumor stem cells

Country Status (11)

Country Link
US (1) US9078857B2 (https=)
EP (2) EP2446895A1 (https=)
JP (4) JP2013540117A (https=)
KR (2) KR101719966B1 (https=)
AU (1) AU2011310109B2 (https=)
CA (1) CA2813101C (https=)
DK (1) DK2621513T3 (https=)
ES (1) ES2616444T3 (https=)
NZ (1) NZ609594A (https=)
PL (1) PL2621513T3 (https=)
WO (1) WO2012042021A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012118547A1 (en) 2010-12-08 2012-09-07 Stem Centrx, Inc. Novel modulators and methods of use
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
EP2733206A1 (en) * 2012-11-19 2014-05-21 Naroa LLC Method for the isolation for mammalian stem cells using EphA2 and uses thereof
CN105828841A (zh) 2013-11-04 2016-08-03 辉瑞大药厂 抗-efna4抗体-药物缀合物
US9777070B2 (en) 2014-04-30 2017-10-03 Pfizer Inc Anti-PTK7 antibody-drug conjugates
JP6921755B2 (ja) 2014-12-10 2021-08-18 ハイパーステム ソシエテ アノニム 脳腫瘍幹細胞の成長、遊走および浸潤性を低下させ脳腫瘍患者の生存率を改善する方法および組成物
CN107851031B (zh) 2015-05-08 2021-05-28 佛罗乔有限责任公司 数据发现节点
IL289849B2 (en) 2015-11-10 2024-01-01 Nat Inst Biotechnology Negev Ltd Means and methods for reducing tumorigenicity of cancer stem cells
JP7680047B2 (ja) * 2020-03-31 2025-05-20 慶應義塾 ゲノム編集多能性幹細胞を用いた治療薬
WO2026022122A1 (en) * 2024-07-23 2026-01-29 Eos Research Sa Checkpoint inhibitors in the treatment of glioblastoma multiforme

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004281834A1 (en) * 2003-10-15 2005-04-28 Cerus Corporation Listeria-based EphA2 vaccines
EP1778726A4 (en) * 2004-08-16 2009-03-18 Medimmune Inc INTEGRIN ANTAGONISTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-ASSAYED CYTOTOXICITY ACTIVITY
US20070248628A1 (en) * 2005-12-06 2007-10-25 Keller Lorraine H Immunogens in cancer stem cells
US8343461B2 (en) * 2006-03-08 2013-01-01 Wake Forest University Health Sciences Molecular signature of cancer
HRP20170407T1 (hr) * 2007-08-30 2017-05-05 Daiichi Sankyo Company, Limited Anti-epha2 anitijelo

Also Published As

Publication number Publication date
WO2012042021A1 (en) 2012-04-05
KR20130095286A (ko) 2013-08-27
JP2013540117A (ja) 2013-10-31
EP2621513A1 (en) 2013-08-07
US20120083454A1 (en) 2012-04-05
JP2016094391A (ja) 2016-05-26
AU2011310109B2 (en) 2014-11-20
EP2446895A1 (en) 2012-05-02
JP2018048151A (ja) 2018-03-29
EP2621513B1 (en) 2016-12-28
ES2616444T3 (es) 2017-06-13
US9078857B2 (en) 2015-07-14
CA2813101A1 (en) 2012-04-05
KR101719966B1 (ko) 2017-03-24
KR20160027106A (ko) 2016-03-09
AU2011310109A1 (en) 2013-05-02
JP2020037579A (ja) 2020-03-12
DK2621513T3 (en) 2017-03-06
PL2621513T3 (pl) 2017-06-30
JP6523910B2 (ja) 2019-06-05
JP6618968B2 (ja) 2019-12-11
NZ609594A (en) 2015-01-30

Similar Documents

Publication Publication Date Title
CA2813101C (en) Eph receptor expression in tumor stem cells
Zhang et al. Interleukin-11 treatment protected against cerebral ischemia/reperfusion injury
AU2015359043C1 (en) Methods and compositions for reducing growth, migration and invasiveness of brain cancer stem cells and improving survival of patients with brian tumors
Atherton et al. Sympathetic modulation of tumor necrosis factor alpha-induced nociception in the presence of oral squamous cell carcinoma
Maisel et al. Stapled EGFR peptide reduces inflammatory breast cancer and inhibits additional HER-driven models of cancer
Abdelazeem et al. Manipulating the EphB4-ephrinB2 axis to reduce metastasis in HNSCC
Fang et al. Enhanced cell growth and tumorigenicity of rat glioma cells by stable expression of human CD133 through multiple molecular actions
Gomez et al. Aberrant hypothalamic neuronal activity blunts glucocorticoid diurnal rhythms in murine breast cancer
US20230190718A1 (en) Methods for the treatment of pancreatitis and prevention of pancreatic cancer
US12186307B2 (en) Methods of treating epilepsy
US12123000B2 (en) Use of PI3KC2B inhibitors for the preservation of vascular endothelial cell barrier integrity
KR20200017495A (ko) Nk-92 세포 및 il-15 효능제의 조합 요법
KR20240052739A (ko) 급성 골수성 백혈병 치료를 위한 wnt5a
Shrouder The pericyte response to ischemic stroke
Nemeth Role of Cell-Type Specific Interleukin-1 Receptor Type 1 Signaling in Lasting Neuroinflammation: The Good, The Bad, and The Irrelevant
Joshi Hypoxic Regulation of Angiotensin-Converting Enzyme 2 and Mas Receptor in Hematopoietic Stem/Progenitor Cells: A Translational Study
CN113144170A (zh) 肽及其在调节巨核细胞分化、治疗血小板相关疾病中的应用
Ma Mechanisms of Brain Edema Formation in Mouse Models of Intracerebral Hemorrhage
SDA THE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1 MONOCLONAL ANTIBODY D16F7 INHIBITS GLIOMA GROWTH AND ANGIOGENESIS IN VIVO
Koodie Effects of chronic morphine treatment on tumor angiogenesis and growth
Wright Role and regulation of G-CSF and its receptor in muscle
Nickerson Transforming Growth Factor Beta Signaling in Growth of Estrogen-Insensitive Metastatic Bone Lesions
Peeters et al. PACAP mediated megakaryopoiesis and thrombopoiesis for the treatment of thrombocytopenia
Miller The negative regulatory effects of LRIG1 on ErbB and Met receptor tyrosine kinases
Walker The role of stromal cell-derived factor-1 in cell mobilization, cell homing, and neovascularization following stroke

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160707

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240926

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240926

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240926

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD

Year of fee payment: 14

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251006

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251006